Ovarian Cancer

An ovarian cancer survivor shares what she wishes she had known then with those who are newly diagnosed.

Knowing your family history is the first preventative step any woman can take to avoid a diagnosis of ovarian cancer.

"I don’t have cancer, but here I am. This is my life. This is my reality. I am BRCA positive."

CURE spoke with an expert on how patients can better advocate for themselves when it comes to genetic testing and its follow-up.

Ovarian Cancer Research Alliance (OCRA) supports women and their families going through an ovarian cancer diagnosis, while also funding the research that will one day lead to its prevention.

Frontline maintenance therapy with Zejula lengthened time without disease progression among women with newly diagnosed, advanced ovarian cancer, according to findings from the phase 3 PRIMA study.

The addition of Lynparza to maintenance therapy with Avastin improved time to disease progression in women with advanced ovarian cancer, according results of the PAOLA-1/ENGOT-ov25 trial.

CURE spoke with an expert from Mount Sinai to discuss the future of ovarian cancer treatment and his advice for women facing a new diagnosis.

“For so long ovarian cancer has been a secret part of my life. That’s over now.”

"I’m a work in progress. I work to heed my oncologist’s advice: Don’t spoil today by worrying about tomorrow."

A rare type of ovarian tumor can raise testosterone levels, causing women to develop male characteristics. The main treatments: surgery and chemotherapy.

September is Ovarian Cancer Awareness Month. Here’s a round-up of the latest news and updates in this disease space.

From a return to work for Alex Trebek to a personalized Backstreet Boys concert, here’s what is making headlines in the cancer space this week.

The US Preventive Services Task Force now recommends for genetic counseling and testing for survivors of certain cancer types, but many at high-risk for the disease are left off the list.

In a new study, Zejula (niraparib) has been shown to prolong life for patients with ovarian cancer who have already undergone four or more rounds of chemotherapy.

Removing lymph nodes that appear unaffected by ovarian cancer won’t help and might hurt.

A recent study found that only a quarter of women with breast cancer and a third of women with ovarian cancer had undergone genetic testing. Memorial Sloan Kettering experts say these numbers are surprisingly low.

One survivor shares how the support of the Cancer Institute at St. Francis and oncology nurse Rose Francucci helped her embrace her cancer journey with positivity.

While recovering from ovarian cancer and chemotherapy, I got it into my head that I needed a garden space. My garden represents not only my physical labor, but also my focus, which is on the future.

By going public with the details of their cancer journeys, patients and survivors can pave the way for understanding and support.

While half of women with gynecologic cancer reported experiencing significant fatigue during treatment, only 8% of survivors had symptoms regress without intervention.

The FDA has granted a priority review designation to a supplemental biologics license application for Zejula for the treatment of certain patients with advanced ovarian, fallopian tube or primary peritoneal cancer.